Marksans Pharma Limited has informed the Exchange regarding a press release dated May 30, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for the product Metformin Hydrochloride 500 mg/ 5ml Oral Solution.".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's wholly-owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from UK regulators for Metformin Hydrochloride 500 mg/5ml Oral Solution. Metformin is a widely used medication for managing type 2 diabetes. With this approval, Relonchem can now market and sell this oral solution formulation in the UK market. The authorization adds a new product to the subsidiary's portfolio in the UK generics space. The company has not disclosed the expected revenue impact or launch timeline in this filing.
This is a positive development as it expands Marksans' UK product portfolio and opens a new revenue stream from the diabetes segment. However, the actual financial impact will depend on market share gained and pricing in the competitive UK generics market.